Q4 revenue up 39% to $6.3M; expects double-digit revenue growth in 2025

Stereotaxis, Inc.

Q4 2024 revenue $6.3M (+39% YoY); full year $26.9M (+0.4% YoY).
Operating loss ($7.6M) in Q4; adjusted operating loss ($4.0M); net loss ($7.5M).
Cash $12.4M, no debt; positive free cash flow of $1.3M in Q4.
2025 guidance: double-digit revenue growth; recurring revenue to scale from $5M Q1 to $7M Q4.
Regulatory milestones: European MAGiC catheter approval, GenesisX first sale, China approvals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.